Compare Baidu Inc (BIDU) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baidu Inc vs Crispr Therapeutics AG — how do they compare? Baidu Inc trades at $104.87 (market cap $36.18B), while Crispr Therapeutics AG trades at $53.98 (market cap $5.23B). The key difference: Baidu Inc is far larger — about 6.9× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| BIDU | CRSP | |
|---|---|---|
Market Cap | $36.18B | $5.23B |
Sector | Media | Health |
52-Week High | $162.52 | $76.78 |
52-Week Low | $86.76 | $44.34 |
Enterprise Value | $32.81B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $104.41, down 4.65% today amid broader pressure on Chinese stocks. The stock shows a bearish technical signal, with recent earnings missing expectations in Q1 2026. Revenue declined to $129.08B in 2025, and net income margin compressed to 1.02%. However, analyst consensus remains strongly bullish with a $169.80 price target, and the company is advancing AI initiatives, including autonomous vehicle testing in London.
The outlook is mixed: strong analyst support and AI growth potential offer upside, but weak profitability, declining revenue, and macroeconomic risks in China pose significant challenges. Investors should weigh the high P/E of 78.19 against future AI-driven earnings acceleration.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
